1. Nezhat FR, Pejovic T, Finger TN, Khalil SS. Role of minimally invasive surgery in ovarian cancer. J Minim Invasive Gynecol. 2013; 20:754–765.
2. Stier EA, Barakat RR, Curtin JP, Brown CL, Jones WB, Hoskins WJ. Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol. 1996; 87((5 Pt 1)):737–740.
3. Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev. 2014; (2):CD009786.
4. Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol. 2014; 25:320–327.
5. Muñoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol. 1997; 15:3408–3415.
6. Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol. 2009; 35:135–143.
7. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114:26–31.
8. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983; 250:3072–3076.
9. Nezhat FR, Ezzati M, Chuang L, Shamshirsaz AA, Rahaman J, Gretz H. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol. 2009; 200:83.e1–83.e6.
10. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008; 108:276–281.
11. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; (8):CD007565.
12. Estes JM, Leath CA 3rd, Straughn JM Jr, Rocconi RP, Kirby TO, Huh WK, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006; 203:527–532.
13. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Gynecologic Oncology Group, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008; 26:83–89.
14. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008; 108:287–292.
15. Narasimhulu DM, Khoury-Collado F, Chi DS. Radical surgery in ovarian cancer. Curr Oncol Rep. 2015; 17:16.
16. Schorge JO, Clark RM, Lee SI, Penson RT. Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? Gynecol Oncol. 2014; 135:595–605.
17. Mikami M. Role of lymphadenectomy for ovarian cancer. J Gynecol Oncol. 2014; 25:279–281.
18. Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol. 1986; 155:315–319.
19. Bentivegna E, Morice P, Uzan C, Gouy S. Fertility-sparing surgery in epithelial ovarian cancer. Future Oncol. 2016; 12:389–398.
20. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011; 205:103–110.
21. Fujiwara K, Kurosaki A, Hasegawa K. Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed? Curr Oncol Rep. 2013; 15:197–200.
22. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007; 104:480–490.
23. Stumpf PG. Practical solutions to improve safety in the obstetrics/gynecology office setting and in the operating room. Obstet Gynecol Clin North Am. 2008; 35:19–35.
24. Gadducci A, Cosio S, Spirito N, Genazzani AR. The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge. Crit Rev Oncol Hematol. 2010; 73:126–140.
25. Wille-Jørgensen P, Rasmussen MS, Andersen BR, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database Syst Rev. 2003; (4):CD001217.
26. Heparin HJ. Heparin. N Engl J Med. 1991; 324:1565–1574.
27. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res. 2003; 109:1–11.
28. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. Cardiol Clin. 2008; 26:145–155.
29. Bauer KA. New anticoagulants. Curr Opin Hematol. 2008; 15:509–515.